Method of optimizing the treatment of Philadelphia-positive leukemia with imatinib mesylate
US8697702B2 · kind B2 · utility
0Cited by
0References
6Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 30, 2009 |
| Grant date | Apr 15, 2014 |
| Priority date | — |
| Expiry date | Dec 5, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a method of treating Philadelphia-positive leukemia (Ph+ leukemia), in a particular chronic myeloid leukemia (CML), in a human patient population. More specifically, the present invention pertains to a method of treating Ph+ leukemia, such as CML or Phi+ ALL, in a human patient suffering from Ph+ leukemia comprising the steps of
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.